Bausch Health Co. Inc. (BHC) Q3 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bausch Health Co. Inc. (BHC) Reports U.S. Launch of BRYHALI (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis in Adults
November 7, 2018 7:23 AM ESTBausch Health Companies Inc. (NYSE: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced it expects to start distribution of BRYHALI (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for BRYHALI Lotion on Nov. 6, 2018. BRYHALI Lotion, which is indicated for the topical treatment of plaque psoriasis in adult patients, is a new potent to superpotent corticosteroid in a novel vehicle lotion with safety established for... More
Bausch Health Companies (BHC) PT Raised to $31 at RBC Capital
November 7, 2018 7:10 AM ESTRBC Capital analyst Doug Miehm raised the price target on Bausch Health Companies (NYSE: BHC) to $31.00 (from $30.00) while maintaining a Sector Perform rating.
... More